University Of Oxford
Clinical trials sponsored by University Of Oxford, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Sleep drug could unlock secrets of depression and anxiety Results expected Sep 2026 (estimated)
- New vaccines aim to block malaria transmission in africa Results expected Sep 2026 (estimated)
- Can support groups help War-Torn families? new trial hopes so Results expected Sep 2026 (estimated)
- Mapping the invisible threat: a feasibility study on antibiotic resistance in the DRC Results expected Sep 2026 (estimated)
- New malaria vaccine trial aims to block the parasite at multiple stages Results expected Oct 2026 (estimated)
-
Can a new vaccine stop malaria in its tracks?
Vaccine Stopped earlyThis early-stage trial is testing a new malaria vaccine candidate, called Pfs48/45, in healthy adults aged 18 to 45 in the UK. The vaccine is designed to block the malaria parasite from spreading, and it's given with an adjuvant called Matrix-M to boost the immune response. The s…
Early phase 1 • Sponsor: University of Oxford • Aim: Vaccine
Last updated Aug 09, 2026 00:00 UTC
-
Early malaria vaccine trial halted – what we know
Vaccine Stopped earlyThis early-stage trial tested a new vaccine against Plasmodium vivax malaria, given with an adjuvant to boost immune response. It involved 25 healthy adults in the UK to check safety and immune reactions. The study was terminated early, so full results are not available.
Early phase 1 • Sponsor: University of Oxford • Aim: Vaccine
Last updated Jun 27, 2026 08:12 UTC
-
UK volunteers test new ebola vaccine combo in Early-Stage trial
Vaccine Stopped earlyThis early-stage trial tested the safety and immune response of two experimental Ebola vaccines in 38 healthy UK adults. Some volunteers received one vaccine, while others got a prime-boost combination. The vaccines use harmless viruses to train the immune system against Ebola wi…
Phase 1 • Sponsor: University of Oxford • Aim: Vaccine
Last updated Jun 27, 2026 08:05 UTC
-
Malaria drug combo safety checked in tiny study
Knowledge-focused Stopped earlyThis early-stage study aimed to see how two common malaria drugs, artemether-lumefantrine and amodiaquine, interact in the body. It enrolled only 8 healthy adults in Thailand and was terminated early. The goal was to measure drug levels and safety when given alone or together.
Phase 1 • Sponsor: University of Oxford • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC